Adocia (ADOC.PA) Osake Kurssi

Adocia SA is primarily active in the pharmaceutical industry.

The main competitors of Adocia SA in the market include other pharmaceutical companies specializing in the development and commercialization of innovative therapies. Some notable competitors of Adocia SA include Novo Nordisk, Sanofi, Eli Lilly, and Johnson & Johnson. These companies are actively involved in the research and development of new treatments for diabetes and other related diseases, similar to Adocia SA.

Adocia SA is a global biotechnology company founded in 2005 and based in France. The company specializes in the development of innovative formulations of proteins and peptides for the treatment of diabetes and other metabolic disorders. Adocia's history is marked by significant milestones, including successful clinical trials and collaborations with leading pharmaceutical companies. With a strong focus on research and development, Adocia has built an impressive intellectual property portfolio and expertise in formulation technology. The company's commitment to improving the lives of patients through advanced therapeutic solutions has positioned Adocia as a key player in the biopharmaceutical industry globally.

Adocia SA has achieved several significant milestones in its journey. One notable achievement is the successful completion of multiple clinical trials for their innovative biopharmaceutical products. Another milestone includes the development and FDA approval of various insulin formulations using their proprietary BioChaperone® technology. Furthermore, Adocia has successfully established partnerships with renowned pharmaceutical companies, expanding its global reach and enhancing its research and development capabilities. These accomplishments demonstrate Adocia SA's commitment to advancing healthcare solutions and solidify its position as a leading player in the biotech industry.

Adocia SA is primarily present in France.

Adocia SA is a pharmaceutical company committed to enhancing the lives of individuals with chronic diseases through innovative drug development. With a strong focus on developing and commercializing therapeutic solutions, Adocia SA prioritizes the well-being and satisfaction of patients. The company champions a corporate philosophy rooted in research excellence, patient-centricity, and collaboration. Adocia SA aims to revolutionize treatment options by leveraging cutting-edge technology and partnerships with industry leaders. By consistently delivering high-quality products, Adocia SA strives to make a lasting positive impact on the healthcare industry, ensuring better outcomes for patients worldwide.

Analyytikot asettavat tällä hetkellä Adocia-osakkeelle keskimääräisen tavoitehinnan 8,87 EUR (mediaani: 8,87 EUR), mikä merkitsee +290,6 % viimeisimpään hintaan verrattuna. Konsensus perustuu 8 analyytikkoarvioon.

Adocia Analyytikkojen kursstavoitteet 2026

9 analyytikkoa arvioi tällä hetkellä Adocia-osaketta: 8 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Adocia-yhtiöltä 3,81 M EUR liikevaihtoa ja −0,89 EUR osakekohtaista tulosta.

Adocia Analyytikkojen kursstavoitteet 2026

Adocia-osake (ADOC.PA) on listattuna 6 pörssissä, muun muassa: London (0QAI.L), Frankfurt (A89.F), München (A89.MU), Düsseldorf (A89.DU), Paris (ADOC.PA).

Adocia SA is a French biotech company that focuses on the development of innovative insulin therapies and other biopharmaceutical preparations. The company's business model is based on researching and developing novel therapy approaches that have a wide range of applications and high efficacy. Adocia operates in three main business areas: diabetes, autoimmune diseases, and cancer. In the diabetes field, the company is working on insulin preparations that help patients with type 1 and type 2 diabetes better control their blood sugar levels. Adocia has developed a range of insulin products, including an ultrafast insulin formulation, a long-acting combination formulation, and a combination formulation with glucagon-like peptide-1 (GLP-1). Adocia is also working on the development of therapies for autoimmune diseases such as Crohn's disease and multiple sclerosis. An innovative product from Adocia is a drug combination developed based on antibodies against tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6). This drug combination has the potential to reduce inflammation in a range of autoimmune diseases. Another important area of business for Adocia is cancer therapy. The company is focused on developing drug combinations based on antibodies and other biological therapies. These drug combinations have the potential to attack cancer cells in various ways while stimulating the body's immune system. To finance the development of these therapies, Adocia has developed an innovative funding model. The company works closely with investment banks and venture capital funds to raise funds necessary for the research and development of new therapy options. Adocia is also involved in successful public offerings and has the opportunity to raise further funding options through issuing shares. Adocia has successfully formed partnerships with other companies in the industry to develop innovative therapies together. The company has also entered into a number of licensing agreements to use the intellectual property of others and improve its own processes and technologies. Overall, Adocia's business model is focused on researching and developing novel therapies for diabetes, autoimmune diseases, and cancer. The company has an impressive product pipeline and a strong funding base that allows it to continue its innovative research efforts. Adocia is a pioneer in the biopharmaceutical industry and is expected to continue to play a crucial role in improving the health of millions of patients worldwide.

odotettu liikevaihto Adocia on 3,81 M EUR. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Adocia on −17,36 M EUR. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Adocia:n hinta-voitto-suhde (P/E) on tällä hetkellä −2,57. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Adocia-osakkeen arvostusta.

Adocia:n hinta-myynti-suhde (P/S) on tällä hetkellä 11,69. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Adocia-osakkeen arvostuskennuslukuna.

Adocia:n Eulpool-laatuscore on 1/10.

Adocia:n ISIN on FR0011184241. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Adocia:n WKN on A1JTC2. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Adocia:n ticker on ADOC.PA. Tämä pörssinoteeraus käytetään Adocia-osakkeiden kauppaan pörssissä.